Lupin launches generic anti-diabetic tablets in US

Pharma major Lupin Ltd has launched its generic version of anti-diabetic medicine dapagliflozin and metformin hydrochloride extended-release tablets in the US. The launched tablets are available in various strengths, including 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg. This launch follows approval from the US health regulator for Lupin's abbreviated new drug application.